Clinical features of CDK4/6 inhibitor-related interstitial lung disease in patients with breast cancer: a case series study.
Chikako FunasakaYoichi NaitoShota KusuharaTakehiro NakaoHiromichi NakajimaMegumi KawamotoKaede BabaKanako MamishinChihiro KondohKenichi HaranoNobuaki MatsubaraAko HosonoTomoaki SasakiToshikatsu KawasakiToru MukoharaPublished in: Japanese journal of clinical oncology (2022)
The frequency of CDK4/6 inhibitor-induced interstitial lung disease was higher than that reported in clinical trials. We did not identify any risk factors for the development of interstitial lung disease in this study, and thus, larger studies that include patient predisposition are required.